The next frontier in longevity science: From drug discovery to living cells

Earlier this year, a Japanese health ministry panel recommended approval of the world’s first two therapies derived from induced pluripotent stem cells (iPSCs). The milestone marked the culmination of nearly two decades of work in regenerative medicine.

One of the therapies repairs a failing heart, while the other restores dopamine production in Parkinson's patients. Both work by replacing cells the body can no longer make on its own.

Their approval marks a category shift from medicine that manages biological decline to medicine that reverses it. And it raises a question that goes well beyond these two therapies: if we can now replace damaged cells in the heart and brain, what does that mean for how we think about ageing itself?

Ageing, at its core, is cellular. Over time, cells accumulate damage, lose function and stop repairing tissue effectively. This underlies nearly every major chronic disease – such as diabetes, Alzheimer's, cardiovascular disease, and Parkinson's – not as separate conditions that emerge unpredictably, but as downstream consequences of the same biological process. As researchers have increasingly recognized, ageing biology sits at the centre of many age-related diseases.

For decades, medicine has treated these diseases as distinct problems. Regenerative medicine asks whether they share a common solution.

IPSCs make that question answerable. Re-programmed from ordinary adult tissue into a youthful, flexible state, iPSCs can differentiate into virtually any cell type in the human body – being they neurons, cardiomyocytes, retinal cells or pancreatic islets. The therapeutic logic is straightforward: rather than temporarily modifying pathways in damaged tissue, replace the tissue.

The challenge has never been the biology; it has been manufacturing.

The February 2026 panel recommendation – and the subsequent approval by Japan's Ministry of Health, Labour and Welfare in March 2026 – matters for reasons beyond the two products themselves.

ReHeart, developed by Cuorips and spun out of Osaka University, uses iPSC-derived cardiomyocyte sheets transplanted onto the surface of the heart for patients with severe ischemic heart failure who have exhausted conventional treatment options. The mechanism is repair through angiogenesis, not symptom management.

Amchepry, developed by Sumitomo Pharma and Racthera, transplants iPSC-derived dopaminergic neural progenitor cells directly into the brain to restore the dopamine signalling that Parkinson's disease destroys.

Both therapies received approval under Japan's conditional and time-limited authorization framework, which requires confirmatory studies following commercialization. They are not finished stories, but they are the first time any regulator anywhere has looked at iPSC-derived therapies and said they are ready for patients.

That threshold matters enormously both for the science and for what it signals to every health system watching.

The supporting evidence was already accumulating. Researchers at Kyoto University Hospital recently reported that iPSC-derived dopaminergic cells survived for two years in Parkinson's disease patients, produced dopamine and showed no evidence of tumor formation.

Meanwhile, in the United States, Vertex Pharmaceuticals reported that zimislecel, an allogeneic pluripotent stem cell-derived islet therapy for type 1 diabetes, eliminated the need for daily insulin in most treated patients.

Different cell sources, different diseases, but the same conclusion – cell therapies can work.

Clinical success does not automatically become clinical scale. The reason is donor variability, one of regenerative medicine's least discussed and most consequential bottlenecks.

Patient-derived iPSCs behave differently depending on genetic background. A manufacturing protocol optimized for one donor can fail completely for the next. Historically, that variability has forced developers into an impossible choice: perform extensive optimization for every patient or accept inconsistency.

Neither is compatible with a functioning healthcare system.

In April, Cellino and Polyphron reported results demonstrating that iPSC lines from genetically diverse donors could be reliably differentiated into high-quality neural tissue despite substantial baseline biological variability. The study also showed that optimal manufacturing conditions could be predicted for new donor lines using limited reference data.

Donor variability, it turns out, is computational problem, not a biological wall. And computational problems have solutions. This matters because the path from two approved therapies in Japan to a global regenerative medicine ecosystem runs directly through manufacturing.

The science is no longer the bottleneck, manufacturing is.

ReHeart and Amchepry are therapies for specific diseases. But the underlying logic applies far more broadly. Ageing remains one of the strongest risk factors for nearly every major chronic disease, because ageing itself drives the gradual decline of cellular function.

If longevity is ultimately a question of how long tissues remain functional: hearts, brains, kidneys, eyes, and pancreas, regenerative medicine becomes central to the future of ageing science.

The economic implications are equally significant. Organisation for Economic Co-operation and Development countries already spend roughly 9–10% of GDP on healthcare, a figure expected to rise as populations age.

The case for investing in regenerative medicine infrastructure today is similar to the case that was once made for semiconductors. The cost of building the capability before it is needed is far lower than the cost of not having it when demand arrives.

The next generation of progress in longevity science will reach beyond consumer wellness into automated cell manufacturing, artificial intelligence (AI)-guided biological engineering, and regulatory frameworks that let proven therapies reach patients faster.

Two approved iPSC therapies is a beginning, not an arrival. The infrastructure still needs to be built. But the biological question of can we replace what the body can no longer repair, now has an answer – and that answer is yes.